How does MA plan design affect utilization & health equity?

The latest stories trending on MedCity News.

Editor's Pick

Top Story Report: How MA Plan Design Affects Utilization, Health Equity A new study found that enrollees with zero-premium MA plans are three times as likely to be non-White compared to other MA enrollees and traditional Medicare enrollees. Premier Healthcare Investing Conference Don't miss out on your opportunity to join us in Chicago for the premier healthcare investing conference of the year. Hurry, you can still save $100. Register Now

Featured News

Which Health Tech Startups Will Present in the Payer/Provider Track of INVEST Pitch Perfect? The finalists for the Payer/Provider track are applying their health tech solutions to addressing burnout and operational efficiency. Overcoming Key Diversity Gaps Within the Healthcare Continuum Leaders need a framework to identify, understand, effectively address diversity gaps, and measure improvement across the continuum of care. A data-driven approach can provide valuable insights into demographic trends, disparities in healthcare access and outcomes, and the underlying factors contributing to these discrepancies. AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med The FDA expanded Enhertu's approval to encompass advanced solid tumors positive for the HER2 cancer protein, regardless of tumor type. Analysts say the regulatory decision paves the way for similar broader approvals of other medications in the ADC cancer drug class. Meet The App UPMC Is Using To Slash Surgical Patients' Readmission Risk by Half UPMC researchers published a study demonstrating the efficacy of Pip Care, a surgical app and healthcare coaching platform. The research showed patients who used Pip Care reduced their hospital stay by nearly a day and cut in half their risk of readmission within a week of surgery compared to those who didn't. Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The Price We Pay for Poor Oral Health To ward off the worsening economic impact and escalating costs associated with neglected oral health in the U.S., we must work with policymakers and state governments to expand access to routine dental healthcare and improve dental insurance availability and service coverage for all.

Resources

A Conversation About Wearable Robots with Scott Davis In this final episode of Season 1, which focuses on the world of medtech, Scott Davis, CEO of Ekso Bionics, delves into the history of the company and the novel devices that Ekso has built. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe